留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝移植领域2017年度重要进展盘点

李海波 符洪源 陆桐宇 曾凯宁 张英才 杨扬

李海波, 符洪源, 陆桐宇, 等. 肝移植领域2017年度重要进展盘点[J]. 器官移植, 2018, 9(1): 41-50,82. doi: 10.3969/j.issn.1674-7445.2018.01.006
引用本文: 李海波, 符洪源, 陆桐宇, 等. 肝移植领域2017年度重要进展盘点[J]. 器官移植, 2018, 9(1): 41-50,82. doi: 10.3969/j.issn.1674-7445.2018.01.006
Li Haibo, Fu Hongyuan, Lu Tongyu, et al. Summary of important research on liver transplantation in 2017[J]. ORGAN TRANSPLANTATION, 2018, 9(1): 41-50,82. doi: 10.3969/j.issn.1674-7445.2018.01.006
Citation: Li Haibo, Fu Hongyuan, Lu Tongyu, et al. Summary of important research on liver transplantation in 2017[J]. ORGAN TRANSPLANTATION, 2018, 9(1): 41-50,82. doi: 10.3969/j.issn.1674-7445.2018.01.006

肝移植领域2017年度重要进展盘点

doi: 10.3969/j.issn.1674-7445.2018.01.006
基金项目: 

国家自然科学基金 81770648

广东省科技计划项目 2017A020215023

中山大学青年教师培育项目 17ykpy57

广东省医学科学技术研究基金项目 A2017370

详细信息
    作者简介:

    李海波,男,1989年生,博士,住院医师,研究方向为肝癌综合治疗及移植免疫等,Email: lhbowh@163.com

    杨扬,教授、主任医师,博士研究生导师。现任中山大学附属第三医院肝脏外科主任,器官移植中心副主任。擅长肝脏、胆道、门静脉高压与胰腺外科疾病的诊断与处理,研究领域包括肝脏移植、移植免疫和干细胞在肝脏疾病的应用等方面。作为负责人获国家自然科学基金4项,863项目分课题1项,十二五国家科技重大专项分题1项,广东省自然科学基金面上项目、重点项目及重点攻关课题7项,广州市科技重点专项1项。以第一或通讯作者发表SCI论文10余篇,副主编2本肝移植专著。获得国家科技部科技进步二等奖1次、教育部科技进步成果一等奖2次、广东省科技进步成果一等奖3次和广州市科技进步成果一等奖1次。“肝脏移植关键技术的建立和推广”获得申报单位团队建设“芙兰奖”

    通讯作者:

    杨扬,Email: yysysu@163.com

  • 中图分类号: R617, R619, R392.4

Summary of important research on liver transplantation in 2017

  • 摘要: 肝移植是目前公认的治疗终末期肝病的最有效措施。经过超过50年的发展,肝移植患者术后存活时间不断延长,并发症的发生率亦有所降低。但是,如何改善供肝短缺的现状、减轻供肝缺血-再灌注损伤,减少并发症的发生率以及进一步提高肝移植患者的远期疗效仍然是困扰肝移植科医师的难题。因此,了解最新的外科技术、多中心临床经验以及相关基础研究结果,将帮助我们更深入地认识疾病本质,为患者制定更妥善的治疗方案。本文综合国际核心期刊报道的内容,对2017年度肝移植相关领域的研究热点及最新进展作一综述,并对今后的研究方向作出展望。
  • [1] RAKHRA SS, OPDAM HI, GLADKIS L, et al. Untapped potential in Australian hospitals for organ donation after circulatory death[J]. Med J Aust, 2017, 207(7): 294-301. DOI: 10.5694/mja16.01405.
    [2] CROOME KP, LEE DD, KEAVENY AP, et al. Improving national results in liver transplantation using grafts from donation after cardiac death donors[J]. Transplantation, 2016, 100(12): 2640-2647. DOI: 10.1097/tp.0000000000001483.
    [3] CROOME KP, LEE DD, PERRY DK, et al. Comparison of longterm outcomes and quality of life in recipients of donation after cardiac death liver grafts with a propensity-matched cohort[J]. Liver Transpl, 2017, 23(3): 342-351. DOI: 10.1002/lt.24713.
    [4] TRIVEDI PJ, SCALERA I, SLANEY E, et al. Clinical outcomes of donation after circulatory death liver transplantation in primary sclerosing cholangitis[J]. J Hepatol, 2017, 67(5): 957-965. DOI: 10.1016/j.jhep.2017.06.027.
    [5] SCHLEGEL A, LINECKER M, KRON P, et al. Risk assessment in high-and low-MELD liver transplantation[J]. Am J Transplant, 2017, 17(4): 1050-1063. DOI: 10.1111/ajt.14065.
    [6] BOHORQUEZ H, SEAL JB, COHEN AJ, et al. Safety and outcomes in 100 consecutive donation after circulatory death liver transplants using a protocol that includes thrombolytic therapy[J]. Am J Transplant, 2017, 17(8): 2155-2164. DOI: 10.1111/ajt.14261.
    [7] DE CARLIS R, DI SANDRO S, LAUTERIO A, et al. Successful donation after cardiac death liver transplants with prolonged warm ischemia time using normothermic regional perfusion[J]. Liver Transpl, 2017, 23(2): 166-173. DOI: 10.1002/lt.24666.
    [8] WATSON CJE, KOSMOLIAPTSIS V, RANDLE LV, et al. Normothermic perfusion in the assessment and preservation of declined livers before transplantation: hyperoxia and vasoplegia-important lessons from the first 12 cases[J]. Transplantation, 2017, 101(5): 1084-1098. DOI: 10.1097/tp.0000000000001661.
    [9] BRAL M, GALA-LOPEZ B, BIGAM D, et al. Preliminary single-center Canadian experience of human normothermic ex vivo liver perfusion: results of a clinical trial[J]. Am J Transplant, 2017, 17(4): 1071-1080.DOI: 10.1111/ajt.1428110.1111/ajt.14049.
    [10] CEPEDA-FRANCO C, BERNAL-BELLIDO C, BARRERA-PULIDO L, et al. Survival outcomes in liver transplantation with elderly donors: analysis of Andalusian Transplant Register[J]. Transplant Proc, 2016, 48(9): 2983-2986. DOI: 10.1016/j.transproceed.2016.09.026.
    [11] SCHLEGEL A, SCALERA I, THAMARA M, et al. Impact of donor age in donation after cardiac death liver transplantation: is the cut-off "60" still of relevance?[J]. Liver Transpl, 2017, DOI: 10.1002/lt.24865[Epub ahead of print].
    [12] BIANCOFIORE G, BINDI M, GHINOLFI D, et al. Octogenarian donors in liver transplantation grant an equivalent perioperative course to ideal young donors[J]. Dig Liver Dis, 2017, 49(6): 676-682. DOI: 10.1016/j.dld.2017.01.149.
    [13] KNAAK M, GOLDARACENA N, DOYLE A, et al. Donor BMI >30 is not a contraindication for live liver donation[J]. Am J Transplant, 2017, 17(3): 754-760. DOI: 10.1111/ajt.14019.
    [14] COMPAGNON P, LEVESQUE E, HENTATI H, et al. An oxygenated and transportable machine perfusion system fully rescues liver grafts exposed to lethal ischemic damage in a pig model of DCD liver transplantation[J]. Transplantation, 2017, 101(7): e205-e213. DOI: 10.1097/tp.0000000000001764.
    [15] KRON P, SCHLEGEL A, MANCINA L, et al. Hypothermic oxygenated perfusion (HOPE) for fatty liver grafts in rats and humans[J]. J Hepatol, 2017, DOI: 10.1016/j.jhep.2017.08.028[Epub ahead of print].
    [16] HE X, JI F, ZHANG Z, et al. Combined liver-kidney perfusion enhances protective effects of normothermic perfusion on livers grafts from donation after cardiac death[J]. Liver Transpl, 2018, 24(1): 67-79. DOI: 10.1002/lt.24954.
    [17] LAING R, BHOGAL RH, WALLACE LW, et al. The use of an acellular oxygen carrier in a human liver model of normothermic machine perfusion[J]. Transplantation, 2017, 101(11): 2746-2756. DOI: 10.1097/tp.0000000000001821.
    [18] GIORGAKIS E, TEDESCHI M, BONACCORSI-RIANI E, et al. The effect of recipient body mass index and its extremes on survival and graft vascular and biliary complications after liver transplantation: a single center retrospective study[J]. Ann Transplant, 2017, 22: 611-621. DOI: 10.12659/AOT.903475.
    [19] AZZAM AZ, TANAKA K. Biliary complications after living donor liver transplantation: a retrospective analysis of the Kyoto experience 1999-2004[J]. Indian J Gastroenterol, 2017, 36(4): 296-304. DOI: 10.1007/s12664-017-0771-3.
    [20] PARK TY, LEE SK, NAM K, et al. Spontaneous hemobilia after liver transplantation: frequency, risk factors, and outcome of endoscopic management[J]. J Gastroenterol Hepatol, 2017, 32(3): 583-588. DOI: 10.1111/jgh.13497.
    [21] APARICIO D, OTOCH JP, MONTERO EFS, et al. Endoscopic approach for management of biliary strictures in liver transplant recipients: a systematic review and Meta-analysis[J]. United European Gastroenterol J, 2017, 5(6): 827-845. DOI: 10.1177/2050640616681909.
    [22] FUJIKI M, HASHIMOTO K, PALAIOS E, et al. Probability, management, and long-term outcomes of biliary complications after hepatic artery thrombosis in liver transplant recipients[J]. Surgery, 2017, 162(5): 1101-1111. DOI: 10.1016/j.surg.2017.07.012.
    [23] INCE V, ERSAN V, KARAKAS S, et al. Does preoperative transarterial chemoembolization for hepatocellular carcinoma increase the incidence of hepatic artery thrombosis after living-donor liver transplant?[J]. Exp Clin Transplant, 2017, 15(Suppl 2): 21-24. DOI: 10.6002/ect.TOND16.L7.
    [24] HERRERO A, SOUCHE R, JOLY E, et al. Early hepatic artery thrombosis after liver transplantation: what is the impact of the arterial reconstruction type?[J]. World J Surg, 2017, 41(8): 2101-2110. DOI: 10.1007/s00268-017-3989-4.
    [25] LI Q, WANG Y, MA T, et al. Impact of cigarette smoking on early complications after liver transplantation:a single-center experience and a Meta-analysis[J]. PLoS One, 2017, 12(5): e0178570. DOI: 10.1371/journal.pone.0178570.
    [26] ROCCARO GA, GOLDBERG DS, HWANG WT, et al. Sustained posttransplantation diabetes is associated with long-term major cardiovascular events following liver transplantation[J]. Am J Transplantation, 2018, 18(1): 207-215. DOI: 10.1111/ajt.14401.
    [27] LEE IJ, KIM SH, LEE SD, et al. Feasibility and midterm results of endovascular treatment of hepatic artery occlusion within 24 hours after living-donor liver transplantation[J]. J Vasc Interv Radiol, 2017, 28(2): 269-275. DOI: 10.1016/j.jvir.2016.06.029.
    [28] YANG L, XIN EY, LIAO B, et al. Development and validation of a nomogram for predicting incidence of early allograft dysfunction following liver transplantation[J]. Transplant Proc, 2017, 49(6): 1357-1363. DOI: 10.1016/j.transproceed.2017.03.083.
    [29] NACIF LS, PINHEIRO RS, DE ARRUDA PÉCORA RA, et al. Re-transplantation, higher creatinine levels in hepatitis C virus patients, and donor age are predictors of mortality in long-term analysis of late acute rejection in liver transplantation[J]. Ann Transplant, 2017, 22: 9-16. DOI: 10.12659/AOT.901010.
    [30] SHAKED A, CHANG BL, BARNES MR, et al. An ectopically expressed serum miRNA signature is prognostic, diagnostic, and biologically related to liver allograft rejection[J]. Hepatology, 2017, 65(1): 269-280. DOI: 10.1002/hep.28786.
    [31] SAN SEGUNDO D, RUIZ P, IRURE J, et al. Serum levels of interleukin-34 during acute rejection in liver transplantation[J]. Transplant Proc, 2016, 48(9): 2977-2979. DOI: 10.1016/j.transproceed.2016.08.038.
    [32] DETRY O, VANDERMEULEN M, DELBOUILLE MH, et al. Infusion of mesenchymal stromal cells after deceased liver transplantation: a phase Ⅰ-Ⅱ, open-label, clinical study[J]. J Hepatol, 2017, 67(1): 47-55. DOI: 10.1016/j.jhep.2017.03.001.
    [33] ABDELHAMID NM, CHEN YC, WANG YC, et al. Pre-transplantation immune cell distribution and early post-transplant fungal infection are the main risk factors of liver transplantation recipients in lower model of end-stage liver disease[J]. Transplant Proc, 2017, 49(1): 92-97. DOI: 10.1016/j.transproceed.2016.11.014.
    [34] MALLET V, HAMED K, SCHWARZINGER M. Prognosis of patients with chronic hepatitis B in France (2008-2013): a nationwide, observational and hospital-based study[J]. J Hepatol, 2017, 66(3): 514-520.DOI: 10.1016/j.jhep.2016.10.031.
    [35] WARREN-GASH C, CHILDS K, THORNTON A, et al. Cirrhosis and liver transplantation in patients co-infected with HIV and hepatitis B or C: an observational cohort study[J]. Infection, 2017, 45(2): 215-220. DOI: 10.1007/s15010-016-0976-x.
    [36] HUI Y, XIANGLI C, XIN W, et al. Clinical outcomes with antiviral prophylaxis or preemptive therapy for cytomegalovirus disease after liver transplantation: a systematic review and Meta-analysis[J]. J Pharm Pharm Sci, 2017, 20:15-27. DOI: 10.18433/j3rc90.
    [37] BUTIN S, GRIFFOUL I, ESPITALIER F, et al. High incidence of vertebral osteoporotic fracture within the first year after liver transplantation[J]. Clin Exp Rheumatol, 2017, 35(6): 913-918. http://www.clinexprheumatol.org/abstract.asp?a=11110
    [38] ALLARD MA, LOPES F, FROSIO F, et al. Extreme large-for-size syndrome after adult liver transplantation: a model for predicting a potentially lethal complication[J]. Liver Transpl, 2017, 23(10): 1294-1304. DOI: 10.1002/lt.24835.
    [39] MEHTA N, HEIMBACH J, LEE D, et al. Wait time of less than 6 and greater than 18 months predicts hepatocellular carcinoma recurrence after liver transplantation: proposing a wait time "sweet spot"[J]. Transplantation, 2017, 101(9): 2071-2078. DOI: 10.1097/tp.0000000000001752.
    [40] PALMER WC, LEE D, BURNS J, et al. Liver transplantation for hepatocellular carcinoma: impact of wait time at a single center[J]. Ann Hepatol, 2017, 16(3): 402-411. DOI: 10.5604/16652681.1235483.
    [41] AGOPIAN VG, HARLANDER-LOCKE MP, RUIZ RM, et al. Impact of pretransplant bridging locoregional therapy for patients with hepatocellular carcinoma within Milan criteria undergoing liver transplantation: analysis of 3 601 patients from the us multicenter HCC transplant consortium[J]. Ann Surg, 2017, 266(3): 525-535. DOI: 10.1097/sla.0000000000002381.
    [42] LEE MW, RAMAN SS, ASVADI NH, et al. Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: a 10-year intention-to-treat analysis[J]. Hepatology, 2017, 65(6): 1979-1990. DOI: 10.1002/hep.29098.
    [43] MEHTA N, HEIMBACH J, HARNOIS DM, et al. Validation of a risk estimation of tumor recurrence after transplant (retreat) score for hepatocellular carcinoma recurrence after liver transplant[J]. JAMA oncol, 2017, 3(4): 493-500. DOI: 10.1001/jamaoncol.2016.5116.
    [44] HALAZUN KJ, NAJJAR M, ABDELMESSIH RM, et al. Recurrence after liver transplantation for hepatocellular carcinoma: a new MORAL to the story[J]. Ann Surg, 265(3): 557-564. DOI: 10.1097/sla.0000000000001966.
    [45] LAI Q, NICOLINI D, INOSTROZA NUNEZ M, et al. A novel prognostic index in patients with hepatocellular cancer waiting for liver transplantation: time-radiological-response-alpha-fetoprotein-inflammation (train) score[J]. Ann Surg, 2016, 264(5): 787-796. DOI: 10.1097/sla.0000000000001881.
    [46] BODZIN AS, LUNSFORD KE, MARKOVIC D, et al. Predicting mortality in patients developing recurrent hepatocellular carcinoma after liver transplantation: impact of treatment modality and recurrence characteristics[J]. Ann Surg, 2017, 266(1): 118-125. DOI: 10.1097/sla.0000000000001894.
    [47] FUNG J, WONG T, CHOK K, et al. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: results up to 8 years[J]. Hepatol, 2017, 66(4): 1036-1044. DOI: 10.1002/hep.29191.
    [48] ULKU A, AKCAM AT, RENCUZOGULLARI A, et al. Effect of dosage and type of hepatitis B immunoglobulin on hepatitis antibody levels in liver transplant recipients[J]. Transplant Proc, 2017, 49(3): 575-579. DOI: 10.1016/j.transproceed.2017.01.024.
    [49] STEPANOVA M, SAYINER M, DE AVILA L, et al. Long-term outcomes of liver transplantation in patients with hepatitis C infection are not affected by HCV positivity of a donor[J]. BMC Gastroenterol, 2016, 16(1): 137. DOI: 10.1186/s12876-016-0551-z.
    [50] DHARANCY S, COILLY A, FOUGEROU-LEURENT C, et al. Direct-acting ANTIVIRAL agent-based regimen for HCV recurrence after combined liver-kidney transplantation: results from the ANRS CO23 CUPILT study[J]. Am J Transplant, 2017, 17(11): 2869-2878. DOI: 10.1111/ajt.14490.
    [51] HUSSAINI T, TURGEON RD, PARTOVI N, et al. Immunosuppression practices in liver transplantation: a survey of north American centers[J]. Exp Clin Transplant, 2017, DOI: 10.6002/ect.2017.0096[Epub ahead of print].
    [52] AGUIAR D, MARTÍNEZ-URBISTONDO D, D'AVOLA D, et al. Conversion from calcineurin inhibitor-based immunosuppression to mycophenolate mofetil in monotherapy reduces risk of de novo malignancies after liver transplantation[J]. Ann Transplant, 2017, 22: 141-147. DOI: 10.12659/AOT.901556.
    [53] O'LEARY JG, CAI J, FREEMAN R, et al. Proposed diagnostic criteria for chronic antibody-mediated rejection in liver allografts[J]. Am J Transplant, 2016, 16(2):603-614. DOI: 10.1111/ajt.13476.
    [54] O'LEARY JG, SMITH C, CAI J, et al. Chronic AMR in liver transplant: validation of the 1-year cAMR score's ability to determine long-term outcome[J]. Transplantation, 2017, 101(9): 2062-2070. DOI: 10.1097/tp.0000000000001802.
    [55] KASAHARA M, UMESHITA K, SAKAMOTO S, et al. Living donor liver transplantation for biliary atresia: an analysis of 2085 cases in the registry of the Japanese liver transplantation society[J]. Am J Transplant, 2017, DOI: 10.1111/ajt.14489[Epub ahead of print].
    [56] KITAJIMA T, SAKAMOTO S, SASAKI K, et al. Living donor liver transplantation for post-Kasai biliary atresia: analysis of pretransplant predictors of outcomes in infants[J]. Liver Transpl, 2017, 23(9): 1199-1209. DOI: 10.1002/lt.24796.
    [57] ALEXOPOULOS SP, NEKRASOV V, CAO S, et al. Effects of recipient size and allograft type on pediatric liver transplantation for biliary atresia[J]. Liver Transpl, 2017, 23(2): 221-233. DOI: 10.1002/lt.24675.
    [58] YANG H, ZHOU H, ZHUANG L, et al. Plasma membrane-bound G protein-coupled bile acid receptor attenuates liver ischemia/reperfusion injury via the inhibition of toll-like receptor 4 signaling in mice[J]. Liver Transpl, 2017, 23(1): 63-74. DOI: 10.1002/lt.24628.
    [59] ZAOUALI MA, PANISELLO A, LOPEZ A, et al. GSK3β and VDAC involvement in er stress and apoptosis modulation during orthotopic liver transplantation[J]. Int J Mol Sci, 2017, 18(3): E591. DOI: 10.3390/ijms18030591.
    [60] SELTEN JW, VERHOEVEN CJ, HEEDFELD V, et al. The release of microRNA-122 during liver preservation is associated with early allograft dysfunction and graft survival after transplantation[J]. Liver Transpl, 2017, 23(7): 946-956. DOI: 10.1002/lt.24766.
    [61] SHEN ZY, WU B, LIU T, et al. Immunomodulatory effects of bone marrow mesenchymal stem cells overexpressing heme oxygenase-1: protective effects on acute rejection following reduced-size liver transplantation in a rat model[J]. Cell Immunol, 2017, 313: 10-24. DOI: 10.1016/j.cellimm.2016.12.006.
    [62] XIE Y, WU Y, XIN K, et al. Delayed donor bone marrow infusion induces liver transplant tolerance[J]. Transplantation, 2017, 101(5): 1056-1066. DOI: 10.1097/tp.0000000000001684.
    [63] SENDRA GISBERT L, MIGUEL MATAS A, SABATER ORTÍ L, et al. Efficacy of hydrodynamic interleukin 10 gene transfer in human liver segments with interest in transplantation[J]. Liver Transpl, 2017, 23(1): 50-62. DOI: 10.1002/lt.24667.
  • 加载中
计量
  • 文章访问数:  41
  • HTML全文浏览量:  11
  • PDF下载量:  0
  • 被引次数: 0
出版历程
  • 收稿日期:  2017-11-29
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2018-01-15

目录

    /

    返回文章
    返回